Stoke outlines Q1 2027 rolling NDA start as EMPEROR enrollment targets June, backed by $411M cash balance

AI Briefing

• – Stoke Therapeutics announces Q1 2027 rolling NDA start, enrollment targets June, and $411M cash balance.
• – The company's EMPEROR trial is on track, with a Phase III timeline.
• – Stoke Therapeutics is focusing on its enrollment targets for the EMPEROR trial in the second half of 2027.